Experimental metabolic homeostasis
Preclinical
2015 mouse and cell data are hypothesis-generating, not a clinical indication.
Also known as mitochondrial open reading frame of the 12S rRNA-c
Mitochondrial-derived peptide studied in cell and mouse metabolic models. Human therapeutic use is not established.
MOTS-c is a peptide encoded in mitochondrial DNA. A 2015 Cell Metabolism paper reported metabolic effects in experimental models, including findings related to insulin sensitivity and diet-induced obesity in mice. These are preclinical results. MOTS-c is not an FDA-approved drug.
MOTS-c is a small peptide that cells can make from mitochondrial genetic material.
It is being studied as a signal that may relate to metabolism and stress responses in experimental systems.
Selling it as an 'exercise mimetic' for people overstates the evidence.
MOTS-c is a tiny protein-like signal from mitochondria. In mice and cells, researchers have seen effects on how the body handles energy and insulin. That is early biology, not a human treatment.
MOTS-c can translocate to the nucleus under stress and influence gene expression related to metabolism in experimental systems. Folate-methionine cycle and AMPK-related hypotheses appear in the 2015 report. Human target engagement at supplement-like exposures is not established.
Step 1
Peptide
MOTS-c
Step 2
Origin / target
Mitochondrial-derived signaling; nuclear gene-expression effects in models
Step 3
Pathway
Metabolic homeostasis pathways in mice/cells
Step 4
Observed research effect
Improved metabolic measures in experimental obesity/insulin-resistance models
2015 mouse and cell data are hypothesis-generating, not a clinical indication.
Adequate interventional human outcome evidence is not sufficiently established on this page.
Lee et al. (2015) reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in mouse models.
2015 · Animal study
Population: Cell and mouse metabolic models
Objective: Describe MOTS-c as a mitochondrial-derived peptide and examine metabolic effects in experimental systems.
Main finding: The study reported metabolic effects of MOTS-c in mice and cells, including findings related to insulin sensitivity and obesity models. These are preclinical results.
Limitations: Animal and cell data do not establish human efficacy, dosing, or safety.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: One landmark mouse paper is not a human evidence base.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Discovery
complete · 2015
Cell Metabolism characterization.
Preclinical research
in progress
Ongoing experimental metabolism work.
Human studies
not started
Adequate trials not established here.
Regulatory status
not started
Not approved.
That claim is not established. Available highlighted evidence is experimental.
No.
Longevity Research
Synthetic tetrapeptide associated with pineal peptide research and aging hypotheses. Human anti-aging efficacy is not established.
View peptide →